Annals of Oncology 12:101-103, 2001
© 2001 European Society for Medical Oncology
research-article |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer
1Second Department of Internal Medicince-Oncology Unit, University of Athens, ‘Ippokratton’ Hospital
2Department of Medical Oncology University General Hospiatl Heration, Crete
3Department of Pathophysiology, University of Athent ‘Laikon General Hospiatl
4Third Department of Medical Oncology, ‘Anargyn’ Anticancer Hospital Athens, Greece
V Georgouhas, MD. PhD Department of Medical Oncology University General Hospital of Heraklion PO Box 1352 71110 Heraklion, Crete Greece E-mail georgoul{at}med.uch.gr
PURPOSE: To evaluate the tolerance and efficacy of front-line docetaxel plus gemcitabine treatment in patients with inoperable pancreatic cancer
PATIENTS AND METHODS: Fifty-four patients with locally advanced or metastatic pancreatic cancer were enrolled. Gemcitabine (1000 mg/m2) was administered on days 1 and 8 and docetaxel (100 mg/m2) on day 8, every three weeks; rh-G-CSF (150 ig/m2 s c) was given prophylactically on days 9–15
RESULTS: Seven (13%) patients achieved partial response and 18 (33%) stable disease (intent-to-treat) The median duration of response was 24 weeks, time to tumour progression 32weeks, and overall survival 26 weeks Performance status was improved in 33% of patients, pain in 43%, asthenia in 16%, weight gain in 28% and appetite in 27% Grade 3–4 neutropenia occurred in 17(31%) patients and grade 3–4 thrombocytopenia in four (4%). Six (11%) patients developed febrile neutropenia and one of them died from sepsis
CONCLUSIONS: This combination is a relatively well-tolerated out-patient regimen for patients with inoperable pancreatic cancer
chemotherapy, docetaxel, gemcitabine, pancreatic cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. J. Chua and J. R. Zalcberg Pancreatic cancer--is the wall crumbling? Ann. Onc., July 1, 2008; 19(7): 1224 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi, et al. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J. Clin. Oncol., June 1, 2007; 25(16): 2212 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Lutz, E. V. Cutsem, T. Wagener, J.-L. Van Laethem, U. Vanhoefer, J. A. Wils, E. Gamelin, C. H. Koehne, J. P. Arnaud, E. Mitry, et al. Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group J. Clin. Oncol., December 20, 2005; 23(36): 9250 - 9256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Xiros, P. Papacostas, T. Economopoulos, G. Samelis, E. Efstathiou, E. Kastritis, H. Kalofonos, A. Onyenadum, D. Skarlos, A. Bamias, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group Ann. Onc., May 1, 2005; 16(5): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Diaz-Rubio New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers Oncologist, June 1, 2004; 9(3): 282 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Stathopoulos, K. Syrigos, A. Polyzos, G. Fountzilas, S. K. Rigatos, N. Ziras, A. Potamiannou, I. Tsiakopoulos, N. Androulakis, G. Aravantinos, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study Ann. Onc., February 1, 2004; 15(2): 224 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Petty, M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, and M. Koruth A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity Ann. Onc., July 1, 2003; 14(7): 1100 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Neoptolemos, D. Cunningham, H. Friess, C. Bassi, D. D. Stocken, D. M. Tait, J. A. Dunn, C. Dervenis, F. Lacaine, H. Hickey, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives Ann. Onc., May 1, 2003; 14(5): 675 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Stathopoulos, S. K. Rigatos, M. A. Dimopoulos, T. Giannakakis, G. Foutzilas, C. Kouroussis, D. Janninis, G. Aravantinos, N. Androulakis, S. Agelaki, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer Ann. Onc., March 1, 2003; 14(3): 388 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Scheithauer, B. Schull, H. Ulrich-Pur, K. Schmid, M. Raderer, K. Haider, W. Kwasny, D. Depisch, B. Schneeweiss, F. Lang, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann. Onc., January 1, 2003; 14(1): 97 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Feliu, R. Mel, P. Borrega, L. Lopez Gomez, P. Escudero, J. Dorta, J. Castro, S. E. Vazquez-Estevez, M. Bolanos, E. Espinosa, et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas Ann. Onc., November 1, 2002; 13(11): 1756 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Louvet, T. Andre, G. Lledo, P. Hammel, H. Bleiberg, C. Bouleuc, E. Gamelin, M. Flesch, E. Cvitkovic, and A. de Gramont Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study J. Clin. Oncol., March 15, 2002; 20(6): 1512 - 1518. [Abstract] [Full Text] [PDF]
|
|